UK markets closed

Nyxoah S.A. (NYXH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
13.49+0.23 (+1.73%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.26
Open13.67
Bid13.27 x 100
Ask13.59 x 100
Day's range13.16 - 13.67
52-week range4.00 - 20.00
Volume12,693
Avg. volume62,580
Market cap395.936M
Beta (5Y monthly)0.49
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

    Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery FoundationFirst medical device company to become a corporate champion at the ENTerprise Circle level Mont-Saint-Guibert, Belgium – March 25, 2024, 7:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sle

  • GlobeNewswire

    Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints

    Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002)Reports an Oxygen Desaturation Index (ODI) responder rate of 71.3% on an intent to treat (ITT) basis (p<0.001)Median 12-month AHI reduction of 70.8% Mont-Saint-Guibert, Belgium – March 19, 2024, 9:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused

  • Globe Newswire

    Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results

    Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating ResultsExpect to report DREAM U.S. pivotal study efficacy and safety data by early AprilAchieved record quarterly sales of €1.8 million Mont-Saint-Guibert, Belgium – March 5, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), to